Subthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02912871|
Recruitment Status : Completed
First Posted : September 23, 2016
Last Update Posted : January 31, 2017
|First Submitted Date ICMJE||August 19, 2016|
|First Posted Date ICMJE||September 23, 2016|
|Last Update Posted Date||January 31, 2017|
|Study Start Date ICMJE||April 2016|
|Actual Primary Completion Date||January 2017 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
|Original Primary Outcome Measures ICMJE||Same as current|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||Subthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson's Disease|
|Official Title ICMJE||A Pilot Clinical Trial of the Feasibility, Safety and Efficacy of Subthalamotomy Using the ExAblate Transcranial System to Treat the Cardinal Motor Features of Parkinson's Disease|
|Brief Summary||Based on published animal and human studies, ExAblate Transcranial subthalamotomy can be as safe and as effective as any of the surgical treatments within the currently accepted standard of care including radiofrequency lesioning and Deep Brain Stimulation (DBS). A unilateral lesion of the subthalamic nucleus has shown reduction of contralateral motor symptoms in Parkinson's disease (PD). Using ExAblate Transcranial Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) to create the subthalamotomy has several potential advantages over current therapies including the fact that transcranial lesioning can be performed in a precise manner with simultaneous as well as continuous clinical and radiographic monitoring. If the potential of ExAblate Transcranial subthalamotomy can be realized, it could supplant radiofrequency and radiosurgery techniques and provide a viable alternative procedure for subjects considering DBS.|
This ExAblate Transcranial system was built atop the ExAblate Body system technology, which has received EMA and CE approvals for the treatment of uterine fibroids and bone metastasis palliation, and is currently being evaluated under various EMA Investigational Device Exemptions "IDE". It should be noted that the ExAblate Transcranial/Neuro has received CE approval (Dec-2012).
There are many potential advantages for applying ExAblate Transcranial subthalamotomy for the treatment of idiopathic PD:
ExAblate Transcranial treatments may represent a simpler treatment algorithm for a patient suffering from a complicated disease process like PD. Hours of clinic time will be saved from DBS device management and replacement and health care costs may be greatly reduced.
- Rational for ExAblate Transcranial System subthalamotomy for the Treatment of PD Conceptually, lesioning the subthalamus seems logical since preclinical studies have confirmed the role of the subthalamic nucleus in the development of parkinsonism and by the fact that the experimental Parkinsonian state by MPTP can be relieved by exocytotic or thermolytic lesions of the STN. Furthermore, clinical studies of deep brain stimulation targeting the subthalamic nucleus have proven that this nucleus is the most effective for the treatment of advanced Parkinson's disease.
From a clinical perspective, unilateral subthalamotomy for medication-refractory Parkinson's disease certainly has proven beneficial in the alleviation of contralateral off-medication motor symptoms in several series. The largest and best reported experience comes from the CIREN (La Habana, Cuba) where this project was initiated and directed by Prof. Jose Obeso over a 10 years period leading to a large accumulated experience. This was described for 89 patients followed for up to 36 months. In these reports, significant improvements were noted on UPDRS ratings with bradykinesia, rigidity and tremor. Improvements remained at two years and were most pronounced for tremor. With regards to the "on" state, contralateral dyskinesia was reduced during the two-year study and the mean dose of Levodopa was decreased by 34-47% while the total on time without dyskinesia increased fourfold. In the study significant reductions in part three of the off-medication UPDRS were noted at 12 (50%), 24 (30%), and 36 months (18%) following unilateral subthalamotomy. In the "on" state, contralateral dyskinesia improved throughout the 3-year study period although ipsilateral dyskinesia progressively worsened during this time. In a limited number of patients bilateral staged ( N-7) and simultaneous ( N-11) subthalamotomy was carried out without major adverse effects and highly significant motor improvement. Cognitive changes were specifically ascertained prospectively without evidence of deterioration. More recently, the impact of unilateral subthalamotomy on inhibitory mechanisms was also reported from the same study group. Unexpectedly, speed of stopping an initiated action was improved after STN lesion.
Subthalamotomy has never been widely accepted because of concerns for hemiballismus primarily due to observations in humans with stroke in the region of the subthalamus (Purdon Martin 1927) and by the confirmation in the 1940's by Whittier and Mettler who were able to experimentally reproduce this by subthalamic lesions in primates. Arguments against such dogma were amply discussed years ago leading to the understanding that the parkinsonian state modifies the threshold to hemiballism after STN lesion.
The ExAblate modality permits a very precise focused lesion to be created without disruption of other motor pathways or nuclei. In order to test the feasibility of using the ExAblate Neuro system for the ablation of the subthalamic nucleus two patients (University of Virginia) were active-sham treated using a sublethal dose of energy (50-54⁰C). The subjects were observed for 30 days without developing any adverse effects like worsening involuntary movements. Since there were no adverse effects of worsening involuntary movements, the actual second stage treatment was then performed. Again, no adverse effects of worsening involuntary movements were observed. The safety profile remains favorable.
Interestingly, the rationale for choosing target temperatures of 50-54⁰C as a ' subtherapeutic/test' lesion was based on the experience acquired during the feasibility study for Essential Tremor under IDE # G10016969 and preclinical lesioning in a swine model. In 15 patients with ET, the typical onset of neurologic phenomena (ie sensory symptoms) or tremor suppression is observed when the peak voxel temperatures on MR thermography reached the low 50's ⁰C. It was observed that the tremor effect first occurs during the titrated lesioning process with transient suppression of postural and rest tremor. Later at higher temperatures of 55-65⁰C, the tremor effect becomes more lasting. Also T2 signal change on MRI is not typically visible acutely in human thalamus until peak voxel temperatures approach this 55-65⁰C range. These higher temperatures resulted in thalamotomy volumes comparable to traditional radiofrequency lesions where the diameter became maximal at 1 week (mean=171 mm3) and measured 6.8mm in diameter. Soon by one and three months, HIFU thalamotomy volumes subsided to 55 and 14 mm3, respectively.
Thus, small lesions with reversible clinical effects would occurre by confining the first, subtherapeutic/test lesion to 50-54⁰C. The therapeutic treatment goal must be to perform the final, peak voxel temperatures of 55-65⁰C which will result in a substantial target ablation which is analogous to the volume achieved with contemporary RF lesioning.
The rationale for unilateral subthalamotomy for advanced PD is summarized as follows:
Summary Based on published animal and human studies, ExAblate Transcranial subthalamotomy can be as safe and as effective as any of the surgical treatments within the currently accepted standard of care including RF lesioning and DBS. A unilateral lesion of the subthalamic nucleus has shown reduction of contralateral motor symptoms in PD. Using ExAblate Transcranial MRgHIFU to create the subthalamotomy has several potential advantages over current therapies including the fact that transcranial lesioning can be performed in a precise manner with simultaneous as well as continuous clinical and radiographic monitoring. If the potential of ExAblate Transcranial subthalamotomy can be realized, it could supplant radiofrequency and radiosurgery techniques and provide a viable alternative procedure for subjects considering DBS.
This study will include ten Parkinson's disease patients who will be treated with unilateral subthalamotomy performed by MRIgHIFU and followed in an open-label fashion for up to 6 months to demonstrate safety and sustained benefit.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Not Applicable|
|Study Design ICMJE||Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Condition ICMJE||Parkinson's Disease|
|Intervention ICMJE||Other: MRIgHIFU unilateral subthalamotomy
High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
|Study Arms ICMJE||Experimental: MRIgHIFU unilateral subthalamotomy
Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
Intervention: Other: MRIgHIFU unilateral subthalamotomy
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Actual Enrollment ICMJE
|Original Actual Enrollment ICMJE||Same as current|
|Actual Study Completion Date ICMJE||January 2017|
|Actual Primary Completion Date||January 2017 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||30 Years and older (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Not Provided|
|Removed Location Countries|
|NCT Number ICMJE||NCT02912871|
|Other Study ID Numbers ICMJE||PD003E|
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement ICMJE||
|Responsible Party||Fundación de investigación HM|
|Study Sponsor ICMJE||Fundación de investigación HM|
|PRS Account||Fundación de investigación HM|
|Verification Date||January 2017|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP